Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL; European paediatric Soft tissue sarcoma Study Group.
Bisogno G, et al. Among authors: kelsey a.
Lancet Oncol. 2018 Aug;19(8):1061-1071. doi: 10.1016/S1470-2045(18)30337-1. Epub 2018 Jun 22.
Lancet Oncol. 2018.
PMID: 29941280
Clinical Trial.